Chemotherapy of leishmaniasis and trypanosomiasis: Advances and failures

Current Opinion in Infectious Diseases

Volumn 9, Issue 6, 1996, Pages 435-438

  Gradoni, Luigi ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTITRYPANOSOMAL AGENT; BENZNIDAZOLE; EFLORNITHINE; MELARSOPROL; NIFURTIMOX;

AFRICAN TRYPANOSOMIASIS; CHAGAS DISEASE; DRUG EFFICACY; DRUG TOLERABILITY; LEISHMANIASIS; SHORT SURVEY; TRYPANOSOMIASIS; VISCERAL LEISHMANIASIS;

EID: 0030443706     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199612000-00016     Document Type: Short Survey

References (30)

1. Olliaro PL, Bryceson ADM: Practical progress and new drugs for changing patterns of leishmaniasis. Parasitol Today 1993, 9:323-328.
2. Gradoni L, Bryceson A, Desjeux P: Treatment of Mediterranean visceral leishmaniasis. Bull WHO 1995, 73:191-197.
3. Davidson RN, di Martino L, Gradoni L, Giacchino R, Russo R, Gaeta GB, Pempinello R, Scotti S, Raimondi F, Cascio A et al.: Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multicentre trial. Q J Med 1994, 87:75-81.
4. Davidson RN, di Martino L, Gradoni L, Giacchino R, Gaeta GB, Pempinello R, Scotti S, Cascio A, Castagnola E, Maisto A et al.: Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome). Clin Infect Dis 1996, 22:938-943. This paper reports a multicentre, dose-ranging clinical trial including 88 immunocompetent patients (56 children). Three groups were treated with total AmBisome doses of 24, 18 and 15 mg/kg, respectively, the follow-up being 1 year or longer. The 18 mg/kg regimen, which consisted of single doses of 3 mg/kg per day on days 1-5 and day 10, was found to be highly effective (98%), well tolerated and had a low hospitalization cost.
5. Thakur CP, Pandey AK, Sinha GP, Roy S, Behbehani K, Olliaro P: Comparison of three treatment regimens with liposomal amphotericin B (AmBisome®) for visceral leishmaniasis in India: a randomized dose finding study. Trans R Soc Trop Med Hyg 1996, 90:319-322.
6. Dietze R, Milan EP, Berman JD, Grogl M, Falqueto A, Feitosa TF, Luz KG, Suassuna FAB, Marinho LAC, Ksionski G: Treatment of Brazilian kala-azar with a short course of Amphocil® (amphotericin B cholesterol dispersion). Clin Infect Dis 1993, 17:981-986.
7. Dietze R, Fagundes SMS, Brito EF, Milan EP, Feitosa TF, Suassuna FAB, Fonschiffrey G, Ksionski G, Dember J: Treatment of kala-azar in Brazil with Amphocil® (amphotericin B cholesterol dispersion) for 5 days. Trans R Soc Trop Med Hyg 1995, 89:309-311.
8. Sundar S, Murray HW: Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex. J Infect Dis 1996, 173:762-765.
9. Jha TK, Giri YN, Singh TK, Jha S: Use of amphotericin B in drug-resistant cases of visceral leishmaniasis in North Bihar, India. Am J Trop Med Hyg 1995, 52:536-538.
10. Chunge CN, Owate J, Pamba HO, Donno L: Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate. Trans R Soc Trop Med Hyg 1990, 84:221-225.
11. Thakur CP, Bhowmick S, Dolfi L, Olliaro P: Aminosidine plus sodium stibogluconate for the treatment of Indian kala-azar: a randomized dose finding clinical trial. Trans R Soc Trop Med Hyg 1995, 89:219-223.
12. Domingo P, Ferrer S, Kolle L, Muñoz C, Rodriguez P: Acute pancreatitis associated with sodium stibogluconate treatment in a patient with human immunodeficiency virus. Arch Intern Med 1996, 156:1029-1032.
13. McBride MO, Linney M, Davidson RN, Weber JN: Pancreatic necrosis following treatment of leishmaniasis with sodium stibogluconate [Letter]. Clin Infect Dis 1995, 21:710. This is the first report on antimony-associated pancreatic necrosis, documented in an AIDS patient on the second day of treatment with pentavalent antimony. The patient had previously been treated with liposomal and conventional amphotericin B, and had suffered repeated relapses. This report should discourage the use of antimonials as maintenance therapy.
14. Russo R, Nigro LC, Minniti S, Montineri A, Gradoni L, Caldeira L, Davidson RN: Visceral leishmaniasis in HIV infected patients: treatment with high dose liposomal amphotericin B (AmBisome). J Infect 1996, 32:133-137.
15. Laguna F, Torre-Cisneros J, Moreno V, Villanueva JL, Valencia E: Efficacy of intermittent liposomal amphotericin B in the treatment of visceral leishmaniasis in patients infected with human immunodeficiency virus. Clin Infect Dis 1995, 21:711-712.
16. Raffi F, Merrien D, Le Pape P, Reliquet V: Use of itraconazole allopurinol combination for the treatment of visceral leishmaniasis in a patient with AIDS. Clin Infect Dis 1995, 21:1338-1339.
17. Torrús D, Boix V, Massa B, Portilla J, Pérez-Mateo M: Fluconazole plus allopurinol in treatment of visceral leishmaniasis. J Antimicrob Chemother 1996, 37:1042-1043. Two AIDS patients who relapsed after, or were intolerant to antimonial treatment, received 400 mg/day fluconazole plus 300 mg/day allopurinol for 3 weeks. This association was also established for maintenance therapy by reducing the fluconazole dosage to 200 mg/day. No replases have occurred during 11 months follow-up. This drug regimen should be investigated further.
18. Ben Salah A, Zakraoui H, Zaatour A, Ftaiti A, Zaafouri B, Garraoui A, Olliaro PL, Dellagi K, Ben Ismail R: A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. Am J Trop Med Hyg 1995, 53:162-166.
19. Asilian A, Jalayer T, Whitworth JAG, Ghasemi RL, Nilforooshzadeh M, Olliaro P: A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran. Am J Trop Med Hyg 1995, 53:648-651.
20. Larbi EB, Al-Khawajah A, Al-Gindan Y, Jain S, Abahusain A, Al-Zayer A: A randomized, double-blind, clinical trial of topical clotrimazole versus miconazole for treatment of cutaneous leishmaniasis in Eastern province of Saudi Arabia. Am J Trop Med Hyg 1995, 52:166-168.
21. Rodriguez LV, Dedet JP, Paredes V, Mendoza C, Cardenas F: A randomized trial on amphotericin B alone or in combination with itraconazole in the treatment of mucocutaneous leishmaniasis. Mem Inst Oswaldo Cruz 90:525-528.
22. El-Hassan AM, Meredith SEO, Yagi HI, Khalil EAG, Ghalib HW, Abbas K, Zijlstra EE, Kroon CCM, Schoone GJ, Ismail A: Sudanese mucosal leishmaniasis: epidemiology, clinical features, diagnosis, immune responses and treatment. Trans R Soc Trop Med Hyg 1995, 89:647-652.
23. Hashim FA, Khalil EAG, Ismail A, El-Hassan AM: Apparently successful treatment of two cases of post kala-azar dermal leishmaniasis with liposomal amphotericin B. Trans R Soc Trop Med Hyg 1995, 89:440. This is the first report on the efficacy of liposomal amphotericin B in dermal leishmaniasis. This finding suggests that the drug is not only sequestered in major macrophage-rich tissues, as previously thought, but can also reach dermal areas at therapeutic levels.
24. Khalil EAG, Nur NM, Zijlstra EE, El-Hassan AM, Davidson RN: Failure of a combination of two antifungal drugs, terbinafine plus itraconazole, in Sudanese post kala-azar dermal leishmaniasis. Trans R Soc Trop Med Hyg 1996, 90:187-188.
25. Murray HW, Hariprashad J: Activity of oral atovaquone alone and in combination with antimony in experimental visceral leishmaniasis. Antimicrob Agents Chemother 1996, 40:586-587.
26. Bhakuni V, Singha UK, Dutta GP, Levy HB, Maheshwan RK: Killing of Leishmania donovani amastigotes by poly ICLC in hamsters. J Interferon Cytokine Res 1996, 16:321-325. In this paper, a powerful immunomodulant polyribonucleotide was found to reduce by some 80% the Leishmania amastigote burden in animals treated for 10 days. Interestingly, the leishmanicidal effect appears to be caused by enhancement of amastigote killing through a nitric oxide-mediated mechanism.
27. Pépin J, Milord F, Khonde AN, Niyonsenga T, Loko L, Mpia B, De Wals P: Risk factors for encephalopathy and mortality during melarsoprol treatment of Trypanosoma brucei gambiense sleeping sickness. Trans R Soc Trop Med Hyg 1995, 89:92-97.
28. Pépin J, Khonde N: Relapses following treatment of early-stage Trypanosoma brucei gambiense sleeping sickness with a combination of pentamidine and suramin. Trans R Soc Trop Med Hyg 1996, 90:183-186.
29. Iten M, Matovu E, Brun R, Kaminsky R: Innate lack of susceptibility of Ugandan Trypanosoma brucei rhodesiense to DL-α-difluoromethyl-ornithine (DFMO). Trop Med Parasitol 1995, 46:190-194.
30. Sànchez G, Zulantay I, Venegas J, Solan A, Gàlvez R, Peña P, Rodriguez J, Apt W: Treatment with allopurinol and itraconazole changes lytic activity in patients with chronic, low grade Trypanosoma cruzi infection. Trans R Soc Trop Med Hyg 1995, 89:438-439.